Assay Detail
Functional
CHEMBL4423157
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiplatelet activity in human platelet rich plasma assessed as inhibition of arachidonic acid-induced platelet aggregation preincubated for 2 mins followed by arachidonic acid addition by turbidimetric method
3
Total Activities
3
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Homo sapiens |
| Tissue | Plasma |
| Cell Type | Platelet |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Publication
Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| IC50 | 3 | 6.17 | 6.35 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL259972 | MOFEZOLAC | 4.0 | 1 | 6.35 |
| CHEMBL4590829 | — | — | 1 | 6.20 |
| CHEMBL25 | ASPIRIN | 4.0 | 1 | 5.96 |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL259972 | MOFEZOLAC | IC50 | = | 450.0 | nM | 6.35 |
| CHEMBL4590829 | — | IC50 | = | 630.0 | nM | 6.20 |
| CHEMBL25 | ASPIRIN | IC50 | = | 1110.0 | nM | 5.96 |